This segment focuses on developing and licensing a pipeline of POCare Therapeutics, which are processed and produced using closed, automated POCare Technology systems within a collaborative POCare Network. The emphasis is on autologous therapies, with processes and systems tailored for each therapy using a closed and automated processing system approach. These systems are validated for compliant production near the patient at their point of care, ensuring timely and effective treatment. The POCare Network integrates patients, doctors, industry partners, research institutes, and hospitals to facilitate the clinical development and production of therapies worldwide. This approach aims to decentralize cell and gene therapy manufacturing, making it more accessible and affordable for patients. Future opportunities include expanding the network and developing new therapeutic applications.

This segment is dedicated to advancing regenerative medicine through the development and acquisition of innovative therapies. A key focus is on spinal cord injury therapies, as demonstrated by the acquisition of certain Neurocords LLC assets. The segment leverages cell and gene therapy technologies to develop solutions that promote tissue repair and functional recovery. Research and development efforts are directed towards creating therapies that can address unmet clinical needs in regenerative medicine. The goal is to improve patient outcomes by providing advanced treatment options that harness the body's natural healing mechanisms. Future opportunities include expanding the portfolio of regenerative medicine therapies and establishing strategic partnerships to accelerate clinical development and commercialization.